Century Therapeutics Q3 net loss $31.2M; cash $244.7M, expands CNTY-101 autoimmune trial, 83% ORR in lymphoma

Century Therapeutics, Inc.

2024-Q3 EPS reported -$1.18 revenue$2,416,000

Net loss $31.2M in Q3 2024; cash $244.7M; expects cash to support operations into H2 2026.
Expanded CNTY-101 autoimmune trial to include diffuse cutaneous systemic sclerosis and idiopathic inflammatory myopathy; basket protocol.
ELiPSE-1 interim: 83% ORR, 33% CRR at DL3B; no DLTs or high-grade CRS/ICANS; DL4B dosing initiated.
Strategic pipeline review to conclude Q1 2025; organizational restructuring extended cash runway.
Appointed Morgan Conn CFO and Chad Cowan CSO; Hy Levitsky transitioned to advisor.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.